Pharmacological and Nanotechnological Approaches in the Treatment of Chronic Pain: Mechanisms, Innovations, and Future Directions
Abstract
Chronic pain is a multifactorial and debilitating condition, often resistant to conventional pharmacological treatments. Despite significant advancements in pain management, patients continue to experience limited efficacy, significant side effects, and challenges in achieving optimal pain control. This article explores the pharmacological mechanisms behind chronic pain and the evolving role of nanotechnology in enhancing drug delivery and improving therapeutic outcomes. The integration of nanomedicine promises to overcome many limitations of current therapies by improving the bioavailability, targeting specificity, and reducing systemic toxicity. By synthesizing recent scientific work, this article highlights the growing promise of nanotechnology, alongside traditional pharmacological strategies, in revolutionizing chronic pain treatment.
Downloads
References
1. Cohn, L., et al. (2021). Interleukine im allergischen Asthma: Mechanismen und therapeutische Implikationen. Immunologie und Allergologie Journal, 29(6), 567-578.
2. Robinson, D. S. (2022). Role of IL-5 in asthma: Mechanism and therapeutic approaches. Clinical Immunology, 99(4), 234-245.
3. Zhang, H., et al. (2023). Nanotechnology in chronic pain management: Challenges and opportunities. Journal of Nanomedicine, 18(3), 122-134.
4. Wang, J., et al. (2022). IL-13: A key mediator in asthma pathogenesis. Frontiers in Immunology, 13, 843-855.
5. Zhang, J., et al. (2024). Gene therapy and nanotechnology in chronic pain treatment. Nanomedicine: Nanotechnology, Biology, and Medicine, 29(1), 45-60.
